United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat
#United Therapeutics #UTHR stock #Earnings beat #Revenue miss #Tyvaso #Q4 results #Healthcare stocks #Inflation Reduction Act
📌 Key Takeaways
- United Therapeutics beat earnings expectations but missed revenue targets in Q4 2026
- The company's stock fell 4.88% in pre-market trading following the announcement
- Full year 2025 revenues reached a record $3.18 billion, reflecting 11% growth over 2024
- Tyvaso DPI showed strong growth of 24% to $338.6 million in Q4
📖 Full Retelling
United Therapeutics Corporation (UTHR) reported fourth quarter results that beat earnings expectations but fell short on revenue in Silver Spring, Md. and Research Triangle Park, N.C. on Wednesday, February 25, 2026, causing its shares to drop 4.88% in pre-market trading despite exceeding profit forecasts. The biopharmaceutical company posted adjusted earnings per share of $7.70 for the fourth quarter, surpassing analyst consensus of $7.10 by $0.60. However, revenue of $790.2 million fell short of expectations of $815.24 million, though it represented a 7% year-over-year increase from $735.9 million in the prior-year quarter. For the full year 2025, United Therapeutics achieved record revenues of $3.18 billion, reflecting 11% growth over 2024, with net income reaching $1.33 billion, up from $1.20 billion in 2024. The company's performance was driven by strong growth in its Tyvaso product line, which saw a 12% increase to $464.3 million in Q4, with Tyvaso DPI increasing 24% to $338.6 million, attributed to increased quantities sold following the product's launch and enhanced commercial utilization after Medicare Part D benefit redesign under the Inflation Reduction Act.
🏷️ Themes
Biopharmaceutical, Earnings Reports, Healthcare Stocks
📚 Related People & Topics
United Therapeutics
American biotech company based in Maryland
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-head...
Treprostinil
Chemical compound
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil was approved for use in the United States in May 2002.
Entity Intersection Graph
Connections for United Therapeutics:
🌐
Biotechnology
1 shared
🌐
Volatility (finance)
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices rebound on tariff jitters; silver, platinum and copper rally Nvidia, Salesforce earnings loom large - what’s moving markets AMD stock surges 14% on Meta AI partnership deal U.S. stock futures drift higher; Nvidia earnings to drive direction (South Africa Philippines Nigeria) United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat By Investing.com Editor Rachael Rajan Earnings Editor Rachael Rajan Published 02/25/2026, 06:37 AM United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat 0 UTHR -0.23% SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported fourth quarter results that beat earnings expectations but fell short on revenue. The company’s shares were down 4.88% in pre-market trading after the announcement. The company posted adjusted EPS of $7.70 for the fourth quarter, surpassing the analyst consensus of $7.10 by $0.60. However, revenue of $790.2 million missed expectations of $815.24 million, though it increased 7% YoY from $735.9 million in the prior-year quarter. Full year 2025 revenues reached a record $3.18 billion, reflecting 11% growth over 2024. Total Tyvaso revenues grew 12% to $464.3 million in the fourth quarter, driven by Tyvaso DPI, which increased 24% to $338.6 million. The growth resulted primarily from increased quantities sold due to continued patient growth following the product’s launch and increased commercial utilization following Medicare Part D benefit redesign under the Inflation Reduction Act. Orenitram revenues rose 12% to $121.2 million. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer. Net income for the quarter was $364.3...
Read full article at source